These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. The effects of oral administration of the novel muscarinic receptor antagonist DA-8010 on overactive bladder in rat with bladder outlet obstruction. Choi JB; Jeon SH; Kwon EB; Bae WJ; Cho HJ; Ha US; Hong SH; Lee JY; Kim SW BMC Urol; 2020 Apr; 20(1):41. PubMed ID: 32303205 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder. Wang CC; Jiang YH; Kuo HC Low Urin Tract Symptoms; 2017 Jan; 9(1):27-32. PubMed ID: 28120445 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment. Gratzke C; Chapple C; Mueller ER; Robinson D; Rolland C; Staskin D; Stoelzel M; Maanen RV; Siddiqui E Eur Urol; 2019 Dec; 76(6):767-779. PubMed ID: 31416636 [TBL] [Abstract][Full Text] [Related]
29. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE). Carlson KV; Rovner ES; Nair KV; Deal AS; Kristy RM; Schermer CR Adv Ther; 2019 Aug; 36(8):1906-1921. PubMed ID: 31222714 [TBL] [Abstract][Full Text] [Related]
30. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Ko Y; Malone DC; Armstrong EP Pharmacotherapy; 2006 Dec; 26(12):1694-702. PubMed ID: 17125433 [TBL] [Abstract][Full Text] [Related]
31. Health Related Quality of Life in Patients with Side-Effects after Antimuscarinic Treatment for Overactive Bladder. Kim A; Lee KS; Jung R; Na S; Kim JC; Kim HG; Choo MS Low Urin Tract Symptoms; 2017 Sep; 9(3):171-175. PubMed ID: 27291463 [TBL] [Abstract][Full Text] [Related]
32. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Abrams P; Andersson KE; Buccafusco JJ; Chapple C; de Groat WC; Fryer AD; Kay G; Laties A; Nathanson NM; Pasricha PJ; Wein AJ Br J Pharmacol; 2006 Jul; 148(5):565-78. PubMed ID: 16751797 [TBL] [Abstract][Full Text] [Related]
33. Current and future pharmacotherapy for treating overactive bladder. Thiagamoorthy G; Cardozo L; Robinson D Expert Opin Pharmacother; 2016 Jul; 17(10):1317-25. PubMed ID: 27253972 [TBL] [Abstract][Full Text] [Related]
35. Older People's Preferences for Side Effects Associated with Antimuscarinic Treatments of Overactive Bladder: A Discrete-Choice Experiment. Decalf VH; Huion AMJ; Benoit DF; Denys MA; Petrovic M; Everaert KCMM Drugs Aging; 2017 Aug; 34(8):615-623. PubMed ID: 28656509 [TBL] [Abstract][Full Text] [Related]
36. Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms. McKeage K Clin Drug Investig; 2013 Jan; 33(1):71-91. PubMed ID: 23288694 [TBL] [Abstract][Full Text] [Related]
37. Trospium chloride treatment of overactive bladder. Biastre K; Burnakis T Ann Pharmacother; 2009 Feb; 43(2):283-95. PubMed ID: 19193592 [TBL] [Abstract][Full Text] [Related]
38. The evolution of transdermal therapy for overactive bladder. Sand PK Curr Urol Rep; 2009 Sep; 10(5):338-41. PubMed ID: 19709479 [TBL] [Abstract][Full Text] [Related]
39. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Rovner ES; Wein AJ Eur Urol; 2002 Jan; 41(1):6-14. PubMed ID: 11999467 [TBL] [Abstract][Full Text] [Related]